3Q Revenues: $11.1 billion (-4%*)
3Q Earnings: $372 million (-89%)
YTD Revenues: $33.9 billion (+1%*)
YTD Earnings: $1.5 billion (-77%)
Comments: Merck posted $9.6 billion in 3Q10 human health revenues, down from $10.1 billion of combined Merck and Schering-Plough sales in 3Q09. Merck put $950 million into reserve to settle an investigation by the Massachusetts district of the U.S. Attorney's Office into Merck's Vioxx marketing practices. In the quarter, Singulair sales rose 12% to $1.2 billion, Januvia sales rose 43% to $247 million, and Cozaar/Hyzaar sales plummeted 51% to $423 million due to generic competition.
* Compared to non-GAAP revenue numbers, intended to reflect combined Merck/Schering-Plough figures for 2009.